Marker Therapeutics, Inc. (MRKR)

USD 4.03

(-17.08%)

Market Cap (In USD)

35.96 Million

Revenue (In USD)

3.31 Million

Net Income (In USD)

-14.04 Million

Avg. Volume

27.21 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.44-6.16
PE
-
EPS
-
Beta Value
1.492
ISIN
US57055L2060
CUSIP
57055L107
CIK
1094038
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Juan F. Vera M.D.
Employee Count
-
Website
https://www.markertherapeutics.com
Ipo Date
2002-07-16
Details
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.